2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020

Join us as we discuss today's pressing healthcare issues.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201102005244/en/

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

Bunny Ellerin, Director, HPM, Columbia Business School, MBA, Harvard Business School, BA, Columbia University (Photo: Business Wire)

CO-HOSTS:

Bunny Ellerin

Director, HPM, Columbia Business School

Jing He

Biotech Analyst, Gabelli Funds

  • MBA, Harvard Business School
  • BA, Columbia University
  • MBA, Columbia Business School
  • MA, Washington University in St. Louis
  • BS, Peking University

Time

Agenda

9:00 – 9:10 AM

Welcome

  • Bunny Ellerin, Director, Healthcare and Pharmaceutical Management Program

9:10 – 10:00 AM

Vaccines & Therapeutics to Treat COVID-19

  • David Hering, Regional President, North America, Pfizer Vaccines
  • Dr. Robert Paris, Vice President, Infectious Diseases, Moderna
  • Dr. David Weinreich, Senior Vice President, Global Clinical Development, Regeneron
  • (Moderator) Jing He ‘15, Biotech Analyst, Gabelli Funds

10:10 – 11:00 AM

Health Policy & Reimbursement Trends

  • Dr. Deepa Kumaraiah, Senior Vice President, Service Lines and Chief Physician, NYP Medical Groups, NewYork-Presbyterian
  • Melissa Schulman, Senior Vice President of Government Affairs, CVS Health
  • Professor Michael Sparer, Chair, Health Policy and Management, Columbia University Mailman School of Public Health
  • (Moderator) Jeff Jonas, Portfolio Manager, Gabelli Funds

11:10 – Noon

Healthcare Delivery in a Virtual World

  • Dr. Amy Fahrenkopf, President, HSS Health and Senior Vice President, Hospital for Special Surgery
  • Jason Gorevic, CEO, Teladoc Health
  • Dr. Julie Silverstein, Divisional President, Oak Street Health
  • (Moderator) Kevin Kedra, Healthcare Analyst, G.research

Click Here to Register

Gabelli Funds, LLC is a registered investment adviser with the Securities and Exchange Commission and is a wholly owned subsidiary of GAMCO Investors, Inc. (NYSE: GBL).

Douglas R. Jamieson
914-921-5020
djamieson@gabelli.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2025

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are... Keep Reading...
 Thian Chew, CEO of Invion

New Deal Could Spark Invion’s Entry into Pet Cancer Market, CEO Says

Invion’s (ASX:IVX,OTC Pink:IVIXF) Photosoft cancer treatment technology has entered an important milestone, thanks to a new collaboration deal with Taiwanese firm Protect Animal Health, to undertake studies to treat cancer in pets.“The significance of this recent collaboration is (that) now... Keep Reading...
Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Appoints global biopharma leader Paul Carter as Non-Executive Director to support next phase of strategic growth

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is delighted to announce the appointment of Paul Carter as Non-Executive Director, effective 27 October 2025.Paul Carter is a highly... Keep Reading...
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs. Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent... Keep Reading...
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded... Keep Reading...

Latest Press Releases

Related News